AI in Drug Development: Who’s the inventor?

AI technologies are being rapidly implemented into drug development pathways, and large pharmaceutical companies are collaborating with smaller technology groups and new start-ups to do so. Whilst these technologies are reducing the cost and time-frame associated with developing a medicine, does AI have the potential to limit a company’s monopoly right over drug discoveries?